Abstract
This study examines the distribution of risk (A) alleles at rs10866912 among 480 individuals stratified by group assignment, gender, age, race/ethnicity, body mass index (BMI), and education level. Preliminary analysis indicated higher prevalence of the risk allele in the population diagnosed with a psychiatric disorder, in concordance with past research. Linear models were applied to elucidate the relationship between the risk allele and various measures covering drug use, diet, psychiatric symptoms, neuropsychiatric ability, and structural brain measures. The findings highlight significant variations in allele frequencies across these measures, in particular egg consumption and analgesic use, which may provide insights into the mechanisms by which this genetic marker influences development of psychiatric disorders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been supported in part by the William K. Warren Foundation and The University of Queensland, Australia. The funders had no role in study design, in the collection, analysis, and interpretation of data, in the writing of the manuscript, or in the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Western-Copernicus Group Institutional Review Board (WCG IRB) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
